Modality
Fusion Protein
MOA
BCL-2i
Target
APOC3
Pathway
Incretin
GAWilms
Development Pipeline
Preclinical
~May 2019
→ ~Aug 2020
Phase 1
Nov 2020
→ Nov 2031
Phase 1Current
NCT07583988
1,052 pts·Wilms
2024-02→TBD·Not yet recruiting
NCT04356679
2,300 pts·GA
2020-11→2031-11·Terminated
3,352 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-11-155.6y awayPh2 Data· GA
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1/2
Termina…
P1/2
Not yet…
Catalysts
Ph2 Data
2031-11-15 · 5.6y away
GA
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07583988 | Phase 1/2 | Wilms | Not yet recr... | 1052 | CR |
| NCT04356679 | Phase 1/2 | GA | Terminated | 2300 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 |